If you are looking for some new portfolio additions, it could be worth checking out the two ASX shares in this article.

After all, they have significant momentum behind them after outstanding performances in 2024.

Let's see what could make them top picks for the year ahead:

Life360 Inc (ASX: 360)

The Life360 share price recorded a stunning gain of 198% in 2024. This was driven by an impressive performance, profitable growth, and the launch of its advertising business. The latter means that the location technology company is now able to monetise its huge subscriber base.

The good news is that Bell Potter believes that this momentum will continue in 2025 and drive further strong growth. So much so, the broker named the company as one of its top tech picks for the year ahead. It said:

The app is used globally by over 75 million people and, of these, there are around 7 million paying subscribers. The penetration rate, therefore, is around 10% and the company has a stated long term target of 30% so there is the potential for the paying subscriber base to triple from here. Life360 is also adding new verticals – like advertising, pet and elderly tracking – which provide additional areas of growth.

The next potential catalysts are when Life360 releases its Q4/2024 result in February – we expect a strong result towards the upper end of the guidance ranges – and the S&P/ASX index rebalance in March where we see a good chance Life360 will be added to the Top 100.

Bell Potter currently has a buy rating and $26.75 price target on its shares.

Pro Medicus Limited (ASX: PME)

Another ASX share that outperformed in 2024 was Pro Medicus. This health imaging technology company's shares recorded a massive 161% gain over the 12 months.

This was driven by another strong financial performance and the announcement of major contract wins thanks to strong demand for its industry leading Visage platform. One of those was a 10-year $330 million contract with Trinity Health.

Goldman Sachs believes the company can build on this in 2025 and beyond. Particularly given its industry-leading Visage platform. It said:

Key reasons for our positive view: (1) We believe the adoption of Visage is a matter of when, not if, for many US healthcare institutions including academics, IDNs and smaller, independent clinics, with our Visage terminal market share expectations >30% amid increasing competition; (2) As a top 5 US IDN, we expect the Trinity contract to drive a network effect across this cohort which represent >40% of PME's core TAM;

(3) We see a significant opportunity to expand customer spend, through existing products (i.e. Cardiology, AI) and new white space products (i.e. other 'ologies'). Amid an intensely competitive AI healthcare market, we believe PME stands out to succeed given its unique partnership with industry KOLs, launching four new solutions with academics at RSNA 2024; and (4) PME has a track record of delivering profitable growth with best in class margins, including >70% under the 'Rule of 40' which we believe is sustainable through the cycle.

The broker has a buy rating and $278.00 price target on the ASX share.